Compare NMZ & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMZ | FTRE |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2023 |
| Metric | NMZ | FTRE |
|---|---|---|
| Price | $10.48 | $17.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.06 |
| AVG Volume (30 Days) | 720.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $9.83 | $4.46 |
| 52 Week High | $10.77 | $18.67 |
| Indicator | NMZ | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 61.52 | 62.63 |
| Support Level | $10.25 | $15.40 |
| Resistance Level | $10.51 | $18.08 |
| Average True Range (ATR) | 0.10 | 0.98 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 98.65 | 73.63 |
Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income exempt from regular federal income tax. The Fund's secondary investment objective is to seek an attractive total return consistent with its primary objective.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.